Literature DB >> 1936497

Mifepristone or vacuum aspiration in termination of early pregnancy.

J Legarth1, U B Peen, J W Michelsen.   

Abstract

This trial compared the termination of early pregnancy (amenorrhoea less than 43 days) by 600 mg orally of the antiprogesteron Mifepristone to the traditional method of vacuum aspiration. Fifty women were randomly assigned to either of the treatments. All the patients treated with vacuum aspiration had a complete abortion. Three of these patients developed pelvic inflammatory diseasae (PID) after the aspiration. Another patient had the uterus perforated during the procedure, and an emergency laparotomy had to be performed. The patients in the evacuation group spent more days in bed and needed longer sick leave after the treatment than the patients in the Mifepristone group. In the Mifepristone group, six patients had incomplete abortions and all were treated by evacuation. Three of the patients developed PID after the evacuation. A decrease of 40% or more in beta hCG from the initial value to the value 1 week later were invariably associated with complete abortion. In both groups the changes in hemoglobin were insignificant and no patients needed blood transfusion or emergency evacuation. The Mifepristone treatment is a simple and safe alternative to vacuum aspiration for termination of early pregnancies.

Entities:  

Keywords:  Abortion, Induced--complications; Biology; Comparative Studies; Contraception; Contraceptive Usage; Denmark; Developed Countries; Endocrine System; Europe; Evaluation; Family Planning; Fertility Control, Postconception; Gonadotropins; Gonadotropins, Chorionic--analysis; Hemic System; Hemoglobin Level--analysis; Hormone Antagonists; Hormones; Method Acceptability; Northern Europe; Physiology; Pregnancy; Pregnancy, First Trimester; Progestational Hormones; Progesterone--analysis; Reproduction; Research Methodology; Ru-486--administraction and dosage; Scandinavia; Studies; Treatment--side effects; Vacuum Aspiration

Mesh:

Substances:

Year:  1991        PMID: 1936497     DOI: 10.1016/0028-2243(91)90085-y

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  2 in total

Review 1.  Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  R N Brogden; K L Goa; D Faulds
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

2.  Prevalence of atrial fibrillation and the risk of cardiovascular mortality among hypertensive elderly population in northeast China.

Authors:  Zhenwei Xia; Wei Dang; Xue Yang; Qun Sun; Jixu Sun; Lei Shi; Shize Sun; Le An; Xiaojing Li; Hongbo Peng; Shuang Liu; Ling Yue; Hongyun Chen
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-04-18       Impact factor: 2.885

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.